CANOGA PARK, Calif.--(BUSINESS WIRE)--One Lambda, Inc. (OLI) announced that it has forged a partnership with CellTrend GmbH, Luckenwalde, Germany, to advance its outreach to the global transplant community. This new alliance is part of a supply agreement, giving OLI worldwide exclusivity to distribute the Immuno-Assay product, EIA for Quantitative Determination of anti-Angiotensin II Receptor 1 (AT1)-Antibodies. This ELISA based application screens antibodies that form against Angiotensin II Type I Receptors (AT1R).
